At Royalty Pharma, our culture fosters an environment in which everyone feels respected and valued and diversity, equity and inclusion (DE&I) are critical. We embrace strong values and take decisive action with and for our employees, counterparties, suppliers and communities.
The information that follows on the diversity of our workforce mirrors the requirements for annual submission to the U.S. Equal Employment Opportunity Commission (EEOC) and reflects our demographics as of December 31, 2023.
The EEOC report speaks as to a single point in time and mandates the use of specific job categories, which do not reflect how we organize our workforce. This representation data is collected from all U.S. employees, including certain temporary employees and interns.
Although it is not possible to fully understand our DE&I journey in a single chart or at a single point in time, we disclose this information because we want to be transparent about our workforce diversity. To learn more about our DE&I strategy and initiatives, please visit our website, www.royaltypharma.com, under ''Responsibility-Building and supporting talent" and the Investors section of our website.
Below are employees that declined to self-identify their race/ethnicity and we were unable to obtain their race information through observer identification and employment records. Job EEO Category 1: 4 Males, Unknown Race/Ethnicity; Job EEO Category 1: 1 Female Unknown Race/Ethnicity; Job EEO Category 2: 2 Females, Unknown Race/Ethnicity; and Job EEO Category 5: 2 Females, Unknown Race/Ethnicity.
SECTION G - CERTIFICATION
Attachments
Original Link
Original Document
Permalink
Disclaimer
Royalty Pharma plc published this content on
03 April 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
10 April 2024 18:56:06 UTC.
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertexâs Trikafta, GSKâs Trelegy, Rocheâs Evrysdi, Johnson & Johnsonâs Tremfya, Biogenâs Tysabri and Spinraza, AbbVie and Johnson & Johnsonâs Imbruvica, Astellas and Pfizerâs Xtandi, Novartisâ Promacta, Pfizerâs Nurtec ODT and Gileadâs Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.